{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:28Z","timestamp":1792453468215,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.msard.2026.107310","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:36:10Z","timestamp":1780842970000},"page":"107310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anti-JCV antibody seroprevalence and testing practices in multiple sclerosis patients considered for natalizumab therapy: a retrospective study from King Saud Medical City, Riyadh, Saudi Arabia"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-644X","authenticated-orcid":false,"given":"Ahmed H.","family":"Althobaiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-6289","authenticated-orcid":false,"given":"Muhamad A","family":"Elrashidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9459-764X","authenticated-orcid":false,"given":"Alanood S.","family":"Alabdulhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2049-8276","authenticated-orcid":false,"given":"Ayah J.","family":"Almuqarrab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9226-1862","authenticated-orcid":false,"given":"Hanadi S.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107310_bib0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2015.11.044","article-title":"JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study","volume":"360","author":"Alroughani","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2026.107310_bib0002","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2013unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107310_bib0003","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/cjn.2014.32","article-title":"Anti-JC virus antibody prevalence in Canadian MS patients","volume":"41","author":"Bhan","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107310_bib0004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"issue":"5-6","key":"10.1016\/j.msard.2026.107310_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000507367","article-title":"Prevalence of anti-JC virus antibody seropositivity in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"62","author":"Hanaei","year":"2019","journal-title":"Intervirology"},{"issue":"11","key":"10.1016\/j.msard.2026.107310_bib0006","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107310_bib0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107310_bib0008","series-title":"Stratify JCV FAQ V.4","year":"2024"},{"key":"10.1016\/j.msard.2026.107310_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/861091","article-title":"Prevalence of anti-JC virus antibody in multiple sclerosis patients in Kuwait","volume":"2014","author":"Lamdhade","year":"2014","journal-title":"ISRN. Neurol."},{"key":"10.1016\/j.msard.2026.107310_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.107310_bib0011","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2026.107310_bib0012","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis","volume":"143","author":"Roos","year":"2020","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.msard.2026.107310_bib0013","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/1352458511429955","article-title":"Anti-JC-virus antibody prevalence in a German MS cohort","volume":"18","author":"Warnke","year":"2012","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2026.107310_bib0014","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:34:05Z","timestamp":1783424045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"alternative-id":["S2211034826003469"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107310","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-JCV antibody seroprevalence and testing practices in multiple sclerosis patients considered for natalizumab therapy: a retrospective study from King Saud Medical City, Riyadh, Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107310"}}